Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net income (loss)	$ 4,134	$ (23,982)	$ 27,193
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation	6,480	6,083	4,957
Amortization of acquisition related intangible assets	7,837	7,381	1,034
Amortization of acquisition related inventory step-up	6,465	11,082	0
Non-cash operating lease cost	1,708	1,531	1,179
Goodwill impairment charge	0	42,520	0
Change in fair value of contingent consideration	(21,095)	(28,666)	0
Loss on disposal of fixed assets	993	265	927
Loss on impairment of intangible asset	600	2,439	389
Stock-based compensation expense	11,085	5,386	6,087
Deferred income taxes	(1,766)	(3,543)	794
Provision (recovery) for doubtful accounts	64	549	(499)
Provision for inventory	6,628	5,490	1,612
Other	(18)	(12)	(25)
Changes in operating assets and liabilities:
Accounts receivable	(6,216)	5,855	(1,839)
Inventories	(6,619)	(14,177)	(5,585)
Prepaid expenses, other current and long-term assets	1,424	(1,783)	(1,641)
Accounts payable	(1,100)	822	767
Operating lease liabilities	(1,626)	(1,439)	(1,065)
Accrued expenses, other current and long-term liabilities	3,510	(142)	3,805
Income taxes	(1,311)	(2,072)	(1,085)
Payments of contingent consideration	(2,780)	(522)	0
Net cash provided by operating activities	8,397	13,065	37,005
Cash flows from investing activities:
Acquisition of Parcus Medical and Arthrosurface, net of cash acquired	(476)	(94,601)	0
Proceeds from maturities of investments	2,501	45,000	146,366
Purchases of investments	0	(20,035)	(103,848)
Purchases of property and equipment	(5,143)	(1,628)	(2,827)
Net cash (used in) provided by investing activities	(3,118)	(71,264)	39,691
Cash flows from financing activities:
Payments made on finance leases	(201)	(208)	0
Proceeds from long term debt	0	50,000	0
Repayments of long term debt	0	(50,350)	0
Repurchases of common stock	0	0	(30,000)
Cash paid for tax withheld on vested restricted stock awards	(486)	(262)	(293)
Proceeds from exercises of equity awards	1,128	1,524	22,151
Payments of contingent consideration	(7,220)	(4,478)	0
Net cash used by financing activities	(6,779)	(3,774)	(8,142)
Exchange rate impact on cash	69	327	(133)
(Decrease) increase in cash and cash equivalents	(1,431)	(61,646)	68,421
Cash and cash equivalents at beginning of period	95,817	157,463	89,042
Cash and cash equivalents at end of period	94,386	95,817	157,463
Supplemental disclosure of cash flow information:
Cash paid for income taxes, net of refunds	1,233	993	9,257
Right-of-use assets obtained in exchange for operating lease liabilities	2,392	2,340
Non-cash investing activities:
Purchases of property and equipment included in accounts payable and accrued expenses	15	17	137
Consideration for acquisitions included in accounts payable and accrued expenses	0	476	0
Contingent consideration fair value on acquisition date	0	69,076	0
Accounting Standards Update 2016-02 [Member]
Supplemental disclosure of cash flow information:
Right-of-use assets obtained in exchange for operating lease liabilities	$ 220	$ 0	$ 24,110